![Efthymios Deliargyris](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Efthymios Deliargyris
Technik-/Wissenschafts-/F&E-Leiter bei CYTOSORBENTS CORPORATION
Vermögen: 368 490 $ am 31.05.2024
Aktive Positionen von Efthymios Deliargyris
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CYTOSORBENTS CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2020 | - |
Karriereverlauf von Efthymios Deliargyris
Ehemalige bekannte Positionen von Efthymios Deliargyris
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PLX PHARMA WINDDOWN CORP. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2018 | 30.04.2020 |
ATHENS MEDICAL C.S.A. | Corporate Officer/Principal | 01.01.2004 | 01.01.2010 |
Wake Forest University | Corporate Officer/Principal | 01.01.2001 | 01.01.2004 |
Ausbildung von Efthymios Deliargyris
National & Kapodistrian University of Athens | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Griechenland | 3 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ATHENS MEDICAL C.S.A. | Health Services |
CYTOSORBENTS CORPORATION | Health Technology |
Private Unternehmen | 1 |
---|---|
PLx Pharma, Inc.
![]() PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE. | Health Technology |
- Börse
- Insiders
- Efthymios Deliargyris
- Erfahrung